Diabetic autonomic neuropathy (DAN) causes morbidity and mortality in patients with diabetes mellitus [1-4]; and among DAN, cardiac autonomic neuropathy (CAN) is an independent risk factor for cardiovascular mortality [5,6]. Although there has been very limited epidemiologic data in Korea, more than 50% of patients with type 2 diabetes mellitus (T2DM) were reported to have DAN in Korea [4,7]. Furthermore, 45.3% of patients with newly detected T2DM had DAN at the time of diagnosis [7]. Current guideline or expert opinions recommend that screening for DAN should be instituted at diagnosis of type 2 diabetes [8-10], even for those who don’t have any symptom of DAN [10].

As CAN is the most studied and clinically important form of DAN, noninvasive tests for CAN are recommended for DAN screening: response to deep breathing, standing, and Valsalva maneuver, and postural blood pressure testing [8,10,11]. Early stages of CAN may be completely asymptomatic and detected only by cardiovascular reflex tests (heart rate variability [HRV] to deep breathing and standing and Valsalva maneuver). HRV can also be assessed by spectral analysis of a series of successive R-R intervals, which can be measured across a range of frequencies and needs less patient participation [12,13]. Quantitative scintigraphic assessment of sympathetic innervation of the human heart [13,14] or quantitative regional measurements of myocardial \( \beta \)-adrenoreceptor density [15] can also be used for the assessment of CAN, of which the results are associated with cardiovascular risks [16]. Other than CAN, DAN also involves gastrointestinal, genitourinary, sudomotor or ocular systems and can be assessed by specific tests associated with its symptoms [10,11].

After identifying individuals at risk of DAN, effective management should be provided. However, at present, the treatment for DAN is limited to glucose control and symptom-based management. The Diabetes Control and Complications Trial demonstrated that intensification of glycemic control can reduce the incidence of CAN by 53% compared with conventional therapy [17]; and Steno-2 study showed that an intensive multifactorial cardiovascular risk intervention targeting blood pressure, lipid, smoking, and lifestyle factors as well as glucose control reduced the progression and development of CAN among T2DM patients [18]. However, multifactorial cardiovascular risk intervention with appropriate glucose control is recommended even for T2DM patients without CAN [8].

Intervention targeting DAN pathogenesis is very limited. A 4-month, randomized controlled clinical trial demonstrated that an antioxidant, \( \alpha \)-lipoic acid, significantly improves CAN in patients with T2DM [19]. ACE-I or ARB also improved DAN in asymptomatic patients with T2DM patients [20]; however, most T2DM use them to manage blood pressure [8]. In diabetic animal model, peroxynitrite decomposition catalysts [21,22] and a selective tyrosine nitration inhibitor [23] have been reported to show neuroprotective effects. However, there has been limited translational works in diabetic patients, and no effective long-term treatment exists to date.
Considering the lack of intervention to alter the DAN pathogenic process, the need for DAN screening should be re-evaluated. It should be confirmed by a randomized controlled trial whether a screening of DAN improves the morbidity, mortality, or quality of life of T2DM patients, especially if they have no related symptom.

However, there are medications to improve symptoms related to DAN, such as orthostatic hypotension, exercise intolerance, constipation, gastroparesis, and erectile dysfunction (reviewed in a review article [10]). Especially in the case of DAN in genitourinary system, appropriate intervention associated with residual urine or voiding difficulty can prevent worsening of renal functions [24] as well as improving voiding [25,26]. Although the presence of autonomic symptoms does not permit the diagnosis of DAN due to its nonspecificity [9], it might be clinically sufficient to check the presence of symptoms related to DAN without HRV evaluation or imaging techniques to confirm the presence of CAN in point of improving the quality of life of T2DM patients. Although autonomic symptoms have been reported to be poorly related to cardiovascular test abnormalities [27] and are not reliable indicators of the presence of autonomic neuropathy [28], we have no effective long-term treatment regimen for DAN except for relief of symptom at present. Kim et al. [29] showed that a symptom-based screening tool; that is, the Survey of Autonomic Symptoms (SAS) scale, was useful in detecting DAN. Considering its simplicity and usefulness to assess symptoms related to DAN, it might help to improve the management of T2DM in real world clinical environment.

Along with the elucidation of long-term effects of screening of DAN on morbidity, mortality, or quality of life in asymptomatic T2DM patients, comparison of the cost-effectiveness, morbidity, or other clinical outcomes between symptom-based versus HRV-based approach in evaluating CAN is warranted at this point. In addition, I’m expecting clinical and translational works to develop medications which can alter the pathologic process of DAN.

**CONFLICTS OF INTEREST**

No potential conflict of interest relevant to this article was reported.

**REFERENCES**

1. Ewing DJ. Cardiovascular reflexes and autonomic neuropathy. Clin Sci Mol Med 1978;55:321-7.
2. Clarke BF, Ewing DJ, Campbell IW. Diabetic autonomic neuropathy. Diabetologia 1979;17:195-212.
3. Vinik AI, Erbas T. Recognizing and treating diabetic autonomic neuropathy. Cleve Clin J Med 2001;68:928-30,32,34-44.
4. Ko SH, Song KH, Park SA, Kim SR, Cha BY, Son HY, Moon KW, Yoo KD, Park YM, Cho JH, Yoon KH, Ahn YB. Cardiovascular autonomic dysfunction predicts acute ischaemic stroke in patients with type 2 diabetes mellitus: a 7-year follow-up study. Diabet Med 2008;25:1171-7.
5. Pop-Busui R, Evans GW, Gerstein HC, Fonseca V, Fleg JL, Hoogwerf BJ, Genuth S, Grimm RH, Horowitz J, Marullo S, Prineas R; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care 2010;33:1578-84.
6. Spallone V, Ziegler D, Freeman R, Bernardi L, Frontoni S, Pop-Busui R, Stevens M, Kempler P, Hilsted J, Tesfaye S, Low P, Valensi P; on behalf of the Toronto Consensus Panel on Diabetic Neuropathy. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev. Epub 2011 Jun 22. DOI: http://dx.doi.org/10.1002/dmrr.1239.
7. Ko SH, Kwon HS, Lee JM, Kim SR, Cho JH, Yoo KD, Park YM, Lee WC, Song KH, Yoon KH, Cha BY, Son HY, Ahn YB. Cardiovascular autonomic neuropathy in patients with type 2 diabetes mellitus. J Korean Diabetes Assoc 2006;30:226-35.
8. American Diabetes Association. Standards of medical care in diabetes: 2014. Diabetes Care 2014;37 Suppl 1:S14-80.
9. Spallone V, Bellaver F, Sciotti L, Maule S, Quadri R, Bax G, Melga P, Viviani GL, Esposito K, Morganti R, Cortelli P; Diabetic Neuropathy Study Group of the Italian Society of Diabetology. Recommendations for the use of cardiovascular tests in diagnosing diabetic autonomic neuropathy. Nutr Metab Cardiovasc Dis 2011;21:69-78.
10. Chun SW, Ko KS. Summary of the update to the diabetic neuropathy management guidebook. J Korean Diabetes 2012;13:115-23.
11. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy: Diabetes Care 2003;26:1553-79.
12. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology.
Heart rate variability: standards of measurement, physiological interpretation and clinical use. Circulation 1996;93:1043-65.
13. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation 2007;115:387-97.
14. Raffel DM, Wieland DM. Assessment of cardiac sympathetic nerve integrity with positron emission tomography. Nucl Med Biol 2001;28:541-59.
15. Caldwell JH, Link JM, Levy WC, Poole JE, Stratton JR. Evidence for pre- to postsynaptic mismatch of the cardiac sympathetic nervous system in ischemic congestive heart failure. J Nucl Med 2008;49:234-41.
16. Stevens MJ, Raffel DM, Allman KC, Dayanikli F, Ficaro E, Sandford T, Wieland DM, Pfeifer MA, Schwaiger M. Cardiac sympathetic dysinnervation in diabetes: implications for enhanced cardiovascular risk. Circulation 1998;98:961-8.
17. The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications (DCCT). Diabetologia 1998;41:416-23.
18. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-93.
19. Ziegler D, Schatz H, Conrad F, Gries FA, Ulrich H, Reichel G. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie. Diabetes Care 1997;20:369-73.
20. Didangelos TP, Ar sos GA, Karamitsos DT, Athyros VG, Georga SD, Karatzas ND. Effect of quinapril or losartan alone and in combination on left ventricular systolic and diastolic functions in asymptomatic patients with diabetic autonomic neuropathy. J Diabetes Complications 2006;20:1-7.
21. Arora M, Kumar A, Kaundal RK, Sharma SS. Amelioration of neurological and biochemical deficits by peroxynitrite decom- position catalysts in experimental diabetic neuropathy. Eur J Pharmacol 2008;596:77-83.
22. Vareniuk I, Pavlov IA, Drel VR, Lyzogubov VV, Ilnytska O, Bell SR, Tibrewala J, Groves JT, Obrosova IG. Nitrosative stress and peripheral diabetic neuropathy in leptin-deficient (ob/ob) mice. Exp Neurol 2007;205:425-36.
23. Al-Gayyar MM, Matra gone S, Pillai BA, Ali TK, Abdelsaid MA, El-Remessy AB. Epicatechin blocks pro-nerve growth factor (proNGF)-mediated retinal neurodegeneration via inhibition of p75 neurotrophin receptor expression in a rat model of diabetes [corrected]. Diabetologia 2011;54:669-80.
24. Hill SR, Fayyad AM, Jones GR. Diabetes mellitus and female lower urinary tract symptoms: a review. Neurourol Urodyn 2008;27:362-7.
25. Saito M, Okada S, Kazuyama E, Satoh I, Kinoshita Y, Satoh K. Pharmacological properties, functional alterations and gene expression of muscarinic receptors in young and old type 2 Goto-Kakizaki diabetic rat bladders. J Urol 2008;180:2701-5.
26. Yang Z, Dolber PC, Fraser MO. Diabetic urethropathy compounds the effects of diabetic cystopathy. J Urol 2007;178:2213-9.
27. Low PA, Benrud-Larson LM, Sletten DM, Opfer-Gehrking TL, Weigand SD, O’Brien PC, Suarez GA, Dyck PJ. Autonomic symptoms and diabetic neuropathy: a population-based study. Diabetes Care 2004;27:2942-7.
28. American Diabetes Association American Academy of Neurology. Consensus statement: report and recommendations of the San Antonio conference on diabetic neuropathy. Diabetes Care 1988;11:592-7.
29. Kim SH, Lee KA, Jin HY, Baek HS, Park TS. Relationship between the Korean version survey of the autonomic symptoms score and cardiac autonomic neuropathy parameters in patients with diabetic peripheral neuropathy. Diabetes Metab J 2014;38;349-55.